What does CUSIP 74366E102 represent in this 13F holders report?

CUSIP 74366E102 is the security identifier for PTGX - Protagonist Therapeutics, Inc - Common Stock used to aggregate holder disclosures.

How many institutions held PTGX - Protagonist Therapeutics, Inc - Common Stock in Q4 2022?

135 institutional investors reported PTGX - Protagonist Therapeutics, Inc - Common Stock for Q4 2022. Use the holders table for investor-level position and value details.

Protagonist Therapeutics, Inc - Common Stock (PTGX)

CUSIP: 74366E102

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class: Equity / Common Stock
Shares outstanding: 63,850,747
Total 13F shares: 49,023,797
Share change: +1,008,365
Total reported value: $534,831,663
Put/Call ratio: 27%
Price per share: $10.91
Number of holders: 135
Value change: +$12,387,471
Number of buys: 71
Number of sells: 57

Quarterly Holders Quick Answers

What is CUSIP 74366E102?
CUSIP 74366E102 identifies PTGX - Protagonist Therapeutics, Inc - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2023
Previous quarter: Q3 2022

Recent filing periods for CUSIP 74366E102:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of PTGX - Protagonist Therapeutics, Inc - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
STATE STREET CORP	13F	Company	7.3%	4,676,682	$39,424,000	—	30 Sep 2022	13F
RTW INVESTMENTS, LP	13F	Company	6.5%	4,176,837	$35,211,000	—	30 Sep 2022	13F
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	5.7%	3,651,887	$30,785,000	—	30 Sep 2022	13F
BlackRock Finance, Inc.	13F	Company	5.4%	3,462,384	$29,188,000	—	30 Sep 2022	13F
VANGUARD GROUP INC	13F	Company	4.6%	2,942,767	$24,807,000	—	30 Sep 2022	13F
FMR LLC	13F	Company	4.4%	2,808,802	$23,679,000	—	30 Sep 2022	13F
Point72 Asset Management, L.P.	13F	Company	4%	2,537,993	$21,395,000	—	30 Sep 2022	13F
JOHNSON & JOHNSON	13F	Company	3.8%	2,449,183	$20,647,000	—	30 Sep 2022	13F
Bain Capital Life Sciences Investors, LLC	13F	Company	3.5%	2,260,572	$19,057,000	—	30 Sep 2022	13F
MORGAN STANLEY	13F	Company	3.5%	2,227,507	$18,777,000	—	30 Sep 2022	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	1.4%	873,045	$7,360,000	—	30 Sep 2022	13F
CITADEL ADVISORS LLC	13F	Company	1.4%	866,387	$7,304,000	—	30 Sep 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.3%	827,456	$6,975,000	—	30 Sep 2022	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	1.3%	820,438	$6,916,000	—	30 Sep 2022	13F
MARSHALL WACE, LLP	13F	Company	1.3%	814,726	$6,869,000	—	30 Sep 2022	13F
DEUTSCHE BANK AG\	13F	Company	1.3%	812,355	$6,848,000	—	30 Sep 2022	13F
GOLDMAN SACHS GROUP INC	13F	Company	1.2%	757,079	$6,382,000	—	30 Sep 2022	13F
Kynam Capital Management, LP	13F	Company	0.81%	519,212	$4,377,000	—	30 Sep 2022	13F
David Y. Liu	3/4/5	Chief R&D Strategy Officer	— class O/S missing	167,590	$4,127,742	—	16 Nov 2022	3/4/5
VOLORIDGE INVESTMENT MANAGEMENT, LLC	13F	Company	0.67%	426,393	$3,594,000	—	30 Sep 2022	13F
NORTHERN TRUST CORP	13F	Company	0.65%	417,783	$3,521,000	—	30 Sep 2022	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.64%	407,300	$3,434,000	—	30 Sep 2022	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.63%	399,767	$3,370,000	—	30 Sep 2022	13F
Rafferty Asset Management, LLC	13F	Company	0.54%	346,935	$2,925,000	—	30 Sep 2022	13F
Nuveen Asset Management, LLC	13F	Company	0.53%	338,544	$2,854,000	—	30 Sep 2022	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.52%	333,643	$2,813,000	—	30 Sep 2022	13F
CITIGROUP INC	13F	Company	0.49%	315,168	$2,657,000	—	30 Sep 2022	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.49%	310,044	$2,614,000	—	30 Sep 2022	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.4%	254,340	$2,144,000	—	30 Sep 2022	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.38%	245,705	$2,071,000	—	30 Sep 2022	13F
SILVERCREST ASSET MANAGEMENT GROUP LLC	13F	Company	0.38%	243,013	$2,049,000	—	30 Sep 2022	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.37%	236,263	$1,991,697	—	30 Sep 2022	13F
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	13F	Company	0.36%	232,820	$1,963,000	—	30 Sep 2022	13F
Russell Investments Group, Ltd.	13F	Company	0.36%	230,847	$1,944,000	—	30 Sep 2022	13F
BARCLAYS PLC	13F	Company	0.34%	215,994	$1,820,000	—	30 Sep 2022	13F
HRT FINANCIAL LP	13F	Company	0.34%	214,097	$1,804,000	—	30 Sep 2022	13F
Gratus Capital, LLC	13F	Company	0.32%	206,113	$1,738,000	—	30 Sep 2022	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.31%	198,022	$1,669,000	—	30 Sep 2022	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.3%	191,193	$1,612,000	—	30 Sep 2022	13F
JPMORGAN CHASE & CO	13F	Company	0.27%	175,559	$1,480,000	—	30 Sep 2022	13F
Bank of New York Mellon Corp	13F	Company	0.25%	158,044	$1,332,000	—	30 Sep 2022	13F
ROTHSCHILD & CO ASSET MANAGEMENT US INC.	13F	Company	0.24%	154,482	$1,302,000	—	30 Sep 2022	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.23%	146,488	$1,235,000	—	30 Sep 2022	13F
VOYA INVESTMENT MANAGEMENT LLC	13F	Company	0.23%	146,459	$1,234,649	—	30 Sep 2022	13F
D. E. Shaw & Co., Inc.	13F	Company	0.22%	143,075	$1,206,000	—	30 Sep 2022	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.21%	137,200	$1,155,000	—	30 Sep 2022	13F
PDT Partners, LLC	13F	Company	0.2%	126,038	$1,063,000	—	30 Sep 2022	13F
Jefferies Group LLC	13F	Company	0.18%	115,500	$973,665	—	30 Sep 2022	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.18%	114,688	$967,000	—	30 Sep 2022	13F
ExodusPoint Capital Management, LP	13F	Company	0.17%	108,876	$918,000	—	30 Sep 2022	13F

Institutional Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q4 2022

As of 31 Dec 2022, Protagonist Therapeutics, Inc - Common Stock (PTGX) was held by 135 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 49,023,797 shares. The largest 10 holders included STATE STREET CORP, BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, RTW INVESTMENTS, LP, VANGUARD GROUP INC, JOHNSON & JOHNSON, MORGAN STANLEY, Bain Capital Life Sciences Investors, LLC, CITADEL ADVISORS LLC, and MARSHALL WACE, LLP. This page lists 136 institutional shareholders reporting positions in this security for the Q4 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders

129

Q4 2022 holders

135

Holder diff

Investor	Q3 2022 Shares	Q4 2022 Shares	Share Diff	Share Chg %	Q3 2022 Value $	Q4 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.